靶向药物联合免疫治疗在原发性肝癌合并微血管侵犯的术后近期复发的价值探讨  

Targeted Drugs Combined with Immunotherapy in Patients with Primary Liver Cancer Complicated with Microvascular Invasion Discussion on the Value of Development

作　　者：曹峰 夏永明 付杰 CAO Feng;XIA Yongming;FU Jie(Department of Hepatobiliary Surgery,Shenzhen Hospital,University of Chinese Academy of Sciences(Guangming),Shenzhen,Guangdong,518107)

机构地区：[1]深圳市光明区人民医院肝胆外科,广东深圳518107

出　　处：《智慧健康》2023年第31期9-12,共4页Smart Healthcare

摘　　要：目的探讨靶向药物联合免疫治疗在原发性肝癌合并微血管侵犯的术后近期复发的价值。方法选取2019年1月—2023年5月本院收治的40例原发性肝癌合并微血管侵犯患者作为研究对象,随机划分为试验组和对照组,每组20例。其中,试验组采用靶向药物联合免疫治疗,对照组采用肝动脉化疗栓塞术治疗。干预后比对试验对象之间的治疗总有效率、T淋巴细胞亚群、复发概率、生活质量测量值。结果治疗工作开展后,所得研究数值治疗总有效率,试验组干预对象评估结果,比对对照组更高(P<0.05);所得研究数值T淋巴细胞亚群,试验组干预对象评估结果CD3+、CD4+,比对对照组更高,CD8+比对对照组更低(P<0.05);所得研究数值复发概率,试验组干预对象评估结果,比对对照组更低(P<0.05);所得研究数值生活质量测量值,试验组干预对象评估结果,比对对照组更高(P<0.05)。结论靶向药物联合免疫治疗投入临床原发性肝癌合并微血管侵犯患者治疗中,所得干预的评估结果更好。治疗后,患者的症状得到较好的改善,且免疫功能得到有效的提升,其复发的情况相对较少,生活水平随之提升,值得被临床应用推广。Objective To observe the clinical treatment of primary liver cancer complicated with vascular invasion,select the use of targeted drug combination.Combined with the effect of immunotherapy intervention measures.Methods selected 40 cases of primary friends admitted to our hospital from January 2019 to May 2023.Patients with hepatic carcinoma complicated with microvascular invasion were randomly divided into experimental group and control group,20 cases in each group.In the trial group,targeted drugs combined with immunotherapy were the specific intervention,and in the control group,liver motility pulse chemoembolization treatment is a specific intervention measure,after the end of the intervention,compared with the total effective treatment between the test subjects T lymphocyte subsets,recurrence of several levels,quality of life measurements.Results After the treatment was carried out,the study saved value treatment,the total effective rate was higher in the experimental group than in the control group(P<0.05);The obtained study value was T lymphatic fine,cell subsets,the evaluation result of the intervention subjects in the experimental group was higher CD3+,CD4+than the control group,and CD8+was lower than the control group(P<0.05);The evaluation result of intervention subjects in experimental group was lower than that in control group(P<0.05).The study value of quality of life measurement,the evaluation result of intervention subjects in experimental group was more different than that in control group(P<0.05).Conclusion Target drug combined immunotherapy was applied in the treatment of clinical patients with primary liver cancer complicated with microvascular invasion,and the evaluation results of the intervention were better.After the implementation of treatment,the symptoms of the patients were better improved,and the immune function was effectively improved,the recurrence of the patients was relatively rare,and the living standard was subsequently improved,which was worthy of clinical application and promo

关 键 词：靶向药物 联合 免疫治疗 原发性肝癌 微血管侵犯 术后 复发 

分 类 号：R735.7[医药卫生—肿瘤]